RT Journal Article
SR Electronic
T1 Intermittent Theta Burst Stimulation (iTBS) and Resting State Functional Connectivity in People Living with HIV/AIDS (PLWHA) Who Smoke Tobacco Cigarettes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.08.23289662
DO 10.1101/2023.05.08.23289662
A1 Rakesh, Gopalkumar
A1 Adams, Thomas G.
A1 Morey, Rajendra A.
A1 Alcorn, Joseph L.
A1 Khanal, Rebika
A1 Su, Amanda E.
A1 Himelhoch, Seth S.
A1 Rush, Craig R.
YR 2023
UL http://medrxiv.org/content/early/2023/05/14/2023.05.08.23289662.abstract
AB Background People living with HIV (PLWHA) smoke at three times the rate of the general population and respond poorly to cessation strategies. Previous studies examined transcranial magnetic stimulation (TMS) over left dorsolateral prefrontal cortex (L. dlPFC) to reduce craving, but no studies have explored TMS among PLWHA who smoke. The current pilot study compared the effects of active and sham intermittent theta-burst stimulation (iTBS) on resting state functional connectivity (rsFC), cigarette cue attentional bias, and cigarette craving in PLWHA who smoke.Methods Eight PLWHA were recruited (single-blind, within-subject design) to receive one session of iTBS (n=8) over the L. dlPFC using neuronavigation and, four weeks later, sham iTBS (n=5). Cigarette craving and attentional bias assessments were completed before and after both iTBS and sham iTBS. rsFC was assessed before iTBS (baseline) and after iTBS and sham iTBS.Results Compared to sham iTBS, iTBS enhanced rsFC between the L. dlPFC and bilateral medial prefrontal cortex and pons. iTBS also enhanced rsFC between the right insula and right occipital cortex compared to sham iTBS. iTBS also decreased cigarette craving and cigarette cue attentional bias.Conclusion iTBS could potentially offer a therapeutic option for smoking cessation in PLWHA.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04936594Funding StatementThis work was supported by the National Institutes of Health (grant numbers AA026255, TR001997, CA225419, MH129832, CX00293, MH111977) and University of Kentucky College of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of University of Kentucky gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors